A and G Pharmaceutical, Inc.

COLUMBIA, MD 21045

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $4.17MM
First Award Date 03/01/04
Most Recent Award Date 09/15/17

Key Personnel

Last Name Name Awards Contact
Serrero Ginette Serrero 8
Hayashi Jun Hayashi Hayashi 2

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/15/17 - 08/31/18

Significance: In 2016, 224,390 new cases of LC and 158,080 related deaths are expected in the US. Of new LC cases ~85% are non-small cell lung cancer (NSCLC) and 70% of these are diagnosed with metastatic/ locally advanced/ inoperable LC with a 5-yr survival of less than 17%. A new approach is required to reduce the overall death rates in this d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 03/15/17 - 03/14/18

Significance: Despite decreases in the overall number of new breast cancer (BC) cases reported in the US annually, there are still about 40,000 BC deaths annually, ~80% from metastatic breast cancer (MBC). Thus the ability to monitor MBC is important to determine disease status and therapy response. While the gold standard, imaging is expensive,...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/15 - 09/21/17

Early detection of cancer is deemed to be a key to successful and cost effective cancer treatment. Routine monitoring of plasma biomarker levels is a non-invasive method for screening for cancer and monitoring for recurrence after treatment. In order to detect the presence of relevant biomarker levels in plasma, high affinity, highly specific ca...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/12 - 02/28/13

DESCRIPTION (provided by applicant): Lung Cancer remains the leading cause of cancer and mortality for men and women worldwide. In 2010, there were 222,520 new cases of lung cancer diagnosed in the US, 85% being non small cell lung cancer (NSCLC) and 157,300 lung cancer related deaths. Clearly, there is a need for additional and novel therap...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/27/11 - 03/31/13

DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until later and these patients are treated using therapies to control both primary tumor and micro-metastatic disease. Therapy response is monitored usin...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 07/01/11 - 06/30/13

DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects induced in patients and insufficient efficacy, particularly for patients with metastatic disease. Targeted cancer therapy is designed to treat...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 07/16/10 - 06/30/11

DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects induced in patients and insufficient efficacy, particularly for patients with metastatic disease. Targeted cancer therapy is designed to treat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 08/01/09 - 07/31/10

DESCRIPTION (provided by applicant): Lck is a Src family non-receptor tyrosine kinase expressed by T lineage lymphocytes. In T cells, Lck plays an essential role in the generation of antigen-mediated activation signals. Since T cell activation is central to mounting immune response, inhibition of Lck blocks T cell activation and suppresses the ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/11/07 - 02/29/08

DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects and insufficient efficacy, particularly for patients with metastatic disease. Targeted cancer therapy is designed to treat only the cancer cel...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/04 - 08/31/04

DESCRIPTION (provided by applicant): Each year 200,000 women in the US are diagnosed with breast cancer, and 40,000 women will die of the disease. Serum diagnosis for screening breast cancer patients is not yet available. Moreover, there is only limited possibility for monitoring response to therapy of breast cancer patients. A serum bioassay t...

Load More